# Ipamorelin FAQ: Weight, Hunger, Safety, and Regulatory Status > Ipamorelin FAQ — does it reduce belly fat, cause weight gain, make you hungry, raise IGF-1, and is it FDA approved? Direct, cited answers from the research. Direct answers to what people actually ask about ipamorelin — body composition, hunger, safety, the CJC-1295 pairing, and legal status — each tied to a study. ## Does ipamorelin reduce belly fat? No human trial has shown ipamorelin reduces belly fat. The animal record is mixed and indirect: ipamorelin shifts body composition through the GH axis, but in mice it actually raised fat-pad weights and leptin [9]. Its most recent study (2024) showed it *protects against* weight loss in a wasting model, not that it strips fat [5]. The "fat loss" idea is an extrapolation from GH biology, not a demonstrated ipamorelin outcome. ## What are the downsides of ipamorelin? The biggest downside is that the evidence is thin and mostly negative in humans: its only Phase 2 trial missed its primary endpoint [3]. Class-level concerns include a chronic cardiotoxicity signal seen with a related ghrelin-receptor agonist in rats [6], unknown long-term human safety, increased appetite from its ghrelin-receptor action [10], and unverified purity of gray-market material [3]. ## Does ipamorelin make you hungry? It can. Ipamorelin activates the ghrelin receptor — the body's "hunger hormone" receptor — and central administration of ghrelin-class agonists switches on the brain's feeding centers in rats [10]. Increased appetite in the hours after a dose is also one of the side effects people report in research-use communities, generally described as milder than with older peptides. It is a mechanistically expected effect, not a guaranteed one. ## Does ipamorelin increase appetite? Yes, by mechanism it tends to. Because ipamorelin is a ghrelin mimic, it engages the same appetite circuitry ghrelin uses; central ghrelin-class agonists induce feeding in rats [10], and mouse data show it raised body weight and leptin in part through GH-independent routes [9]. Community reports describe a noticeable uptick in hunger after dosing. The effect is real at the class level, though its strength varies between individuals. ## Does ipamorelin cause water retention? Mild water retention is an occasionally reported side effect in research-use communities, usually described as puffiness in the fingers, ankles, or face during the first two to four weeks and milder than with older GHRPs. There is no controlled human ipamorelin trial quantifying fluid retention; the one Phase 2 trial reported overall adverse events but did not establish this as a specific drug effect [3]. Treat it as anecdotal. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers growth hormone release by activating the ghrelin / GHS-R1a receptor on the pituitary. Its defining feature, established in 1998, is that it releases GH potently without raising cortisol or prolactin even at very high doses [1]. It is a research peptide, not an approved drug. ## What does ipamorelin do for you? In studies, ipamorelin causes the pituitary to release a clean pulse of growth hormone without the stress-hormone spillover of older peptides [1]. Downstream, growth hormone influences body composition, tissue repair, and metabolism. In animals this translated to bone growth and body-composition shifts [4][9]; in the one human efficacy trial, it did not produce the intended benefit [3]. Human "benefits" remain unproven. ## What is ipamorelin peptide? Ipamorelin peptide is the same compound described throughout this site: a wholly synthetic pentapeptide, molecular formula C38H49N9O5, engineered with non-natural amino acids to resist enzymatic breakdown, that mimics ghrelin at the GHS-R1a receptor to release growth hormone selectively [1]. It is supplied as a freeze-dried powder for research and is not orally active in its native form [7]. ## What are the risks of ipamorelin? Documented risks and gaps include: a class-level cardiotoxicity signal from a related ghrelin-receptor agonist in a 28-day rat study [6]; theoretical IGF-1/cancer concerns from GH-axis stimulation [4]; unpredictable blood-sugar effects in people with diabetes given its direct pancreatic action [16]; increased appetite [10]; and an almost complete absence of long-term human safety data beyond one short trial [3]. Material purity from unregulated suppliers is also unverified [3]. ## Why is ipamorelin being discontinued? Ipamorelin was never an approved drug, so it was not "discontinued" in the usual sense — its clinical development simply stopped after its only Phase 2 trial (for postoperative ileus) missed its primary endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at an October 2024 advisory meeting, tightening compounding-pharmacy access. Falling availability reflects regulatory action plus a failed efficacy program. ## What does CJC-1295 and ipamorelin do? Together they stimulate growth hormone from two different receptors at once: CJC-1295 (a long-acting GHRH analog) provides a steady push, and ipamorelin (a GHRP) adds a pulsatile push on the ghrelin receptor. Combined GHRP + GHRH stimulation drove greater GH output than either alone in controlled human work [15]. The combination is a community protocol, not a trial-validated or approved therapy. ## Does ipamorelin increase IGF-1? Not always, and that surprises people. In short rat studies, ipamorelin grew bone with **no** measurable change in total IGF-1 [4] — the GH pulse did local work without moving the systemic IGF-1 number. By contrast, sustained combined GHRP-2/GHRH stimulation over 30 days held IGF-1 elevated in humans [15]. So IGF-1 elevation depends on how continuous the stimulus is; brief pulsed dosing may not move it much. ## How does CJC-1295 ipamorelin work? CJC-1295 acts on the GHRH receptor and ipamorelin acts on the separate ghrelin (GHS-R1a) receptor, so the two stimulate growth hormone through complementary pathways that converge on the pituitary [1]. Pulsatile GH secretion persists even during continuous GHRH-pathway stimulation [15], which is the physiological logic for layering a pulsatile GHRP on a steady GHRH analog. It is mechanistically coherent but not validated as a combination in trials. ## How much CJC-1295 ipamorelin should I take? There is no evidence-based dose. No controlled human trial has tested the CJC-1295 + ipamorelin combination for any outcome, so no validated amount, ratio, or schedule exists. Community subcutaneous protocols are not supported by peer-reviewed human dosing data and are anecdotal only. The single controlled human ipamorelin regimen on record (0.03 mg/kg IV twice daily) was a hospital trial dose that failed [3], not a self-use template. ## Does CJC-1295 ipamorelin work? For acutely raising growth hormone, the mechanism works — combined GHRP + GHRH stimulation increased GH output more than either agonist alone in humans [15]. For the body-composition and anti-aging outcomes people actually want, no controlled human trial of the combination has demonstrated them, and ipamorelin's solo human efficacy trial failed [3]. The GH-raising effect is supported; the real-world results are not proven. ## How to reconstitute CJC-1295 ipamorelin 5mg? The research-supply literature documents only general peptide handling: ipamorelin ships as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water, then kept refrigerated because it degrades with heat and freeze-thaw cycles. These are handling observations, not a clinical preparation procedure or a human-use protocol. No validated human reconstitution or dosing method exists for ipamorelin, alone or with CJC-1295. ## How long does ipamorelin stay in your system? In healthy human volunteers, ipamorelin had a terminal half-life of approximately 2 hours [2], meaning the bulk of a dose clears within several hours. The growth-hormone pulse it triggers peaks about 40 minutes after dosing as a single discrete spike [2]. Standard pharmacokinetic estimates put near-complete elimination of the peptide itself within roughly a day, though anti-doping assays can detect it and its metabolites for longer windows. ## Will I gain weight on ipamorelin? No human trial answers this. In animals, ipamorelin can increase body weight and appetite through GH-dependent and GH-independent routes [9][10], yet in a 2024 wasting model it protected against weight *loss* [5]. Real-world results are heavily confounded by diet and training, and community reports of a leaner look are anecdotal [labeled on the effects page]. The mechanism can move weight in either direction; the human proof isn't there [3]. ## What does ipamorelin peptide do? Ipamorelin peptide selectively releases growth hormone by activating the ghrelin / GHS-R1a receptor on the pituitary, producing a clean GH pulse without raising cortisol or prolactin [1]. Downstream, that GH influences body composition, bone, and tissue repair — effects documented in animals [4][9] but not confirmed as benefits in the one human efficacy trial, which failed [3]. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after a dose in humans [2]. But that is the hormone response, not a visible result. Any body-composition or recovery effects people describe build over weeks — community reports place sleep changes in the first one to two weeks and composition changes around weeks five to twelve — and none of those timelines come from controlled human trials [2]. ## Where to inject CJC-1295 ipamorelin? This site does not provide injection instructions. In the research literature, ghrelin-class peptides and GHRH analogs have been studied subcutaneously, intravenously, and intraperitoneally depending on the model [15], but there is no validated human self-administration protocol for the CJC-1295 + ipamorelin combination. Community subcutaneous practices are anecdotal and not supported by peer-reviewed human data. ## Does ipamorelin cause cancer? No study has shown ipamorelin causes cancer, and no human carcinogenicity trial exists. The concern is purely theoretical and mechanistic: growth hormone raises IGF-1, a signal that promotes cell growth, so chronically elevating GH pulses raises a general question about pre-existing or hidden tumors [4]. This is a reason for caution in people with active malignancy, not evidence of a cancer-causing effect — the ipamorelin-specific long-term human data simply does not exist. --- A forward-looking, fully cited read of the ipamorelin research record and its regulatory status — a reading console, not a clinic, not a vendor, not a prescription, and not legal advice.